ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 182 filers reported holding ASCENDIS PHARMA A/S in Q1 2022. The put-call ratio across all filers is 0.64 and the average weighting 0.8%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,180,502 | -4.3% | 76,682 | -8.8% | 0.00% | 0.0% |
Q2 2023 | $7,506,104 | -47.4% | 84,102 | -36.9% | 0.00% | -50.0% |
Q1 2023 | $14,283,635 | +41.0% | 133,218 | +60.6% | 0.00% | +100.0% |
Q4 2022 | $10,129,829 | -42.8% | 82,943 | -51.6% | 0.00% | -50.0% |
Q3 2022 | $17,705,000 | -3.0% | 171,457 | -12.7% | 0.00% | 0.0% |
Q2 2022 | $18,253,000 | +45.8% | 196,347 | +84.1% | 0.00% | 0.0% |
Q1 2022 | $12,520,000 | +46.4% | 106,679 | +67.8% | 0.00% | +100.0% |
Q4 2021 | $8,551,000 | -7.7% | 63,567 | +9.4% | 0.00% | 0.0% |
Q3 2021 | $9,265,000 | -10.1% | 58,128 | -25.8% | 0.00% | 0.0% |
Q2 2021 | $10,307,000 | +185.5% | 78,350 | +179.8% | 0.00% | 0.0% |
Q1 2021 | $3,610,000 | -57.3% | 28,007 | -44.7% | 0.00% | 0.0% |
Q4 2020 | $8,450,000 | +1694.1% | 50,660 | +1558.8% | 0.00% | – |
Q3 2020 | $471,000 | +11.6% | 3,054 | +7.0% | 0.00% | – |
Q2 2020 | $422,000 | +60.5% | 2,854 | +22.3% | 0.00% | – |
Q1 2020 | $263,000 | -72.4% | 2,334 | -65.9% | 0.00% | – |
Q4 2019 | $952,000 | +229.4% | 6,842 | +128.3% | 0.00% | – |
Q3 2019 | $289,000 | +71.0% | 2,997 | +104.2% | 0.00% | – |
Q2 2019 | $169,000 | -63.9% | 1,468 | -63.1% | 0.00% | – |
Q1 2019 | $468,000 | -75.6% | 3,975 | -87.0% | 0.00% | -100.0% |
Q4 2018 | $1,915,000 | -42.6% | 30,563 | -35.1% | 0.00% | 0.0% |
Q3 2018 | $3,338,000 | +63.6% | 47,100 | +53.6% | 0.00% | 0.0% |
Q2 2018 | $2,040,000 | +127.7% | 30,666 | +123.8% | 0.00% | – |
Q1 2018 | $896,000 | -64.9% | 13,703 | -78.5% | 0.00% | -100.0% |
Q4 2017 | $2,552,000 | +4.5% | 63,692 | -5.4% | 0.00% | 0.0% |
Q3 2017 | $2,441,000 | +115.3% | 67,332 | +64.9% | 0.00% | – |
Q2 2017 | $1,134,000 | +97.6% | 40,830 | +99.4% | 0.00% | – |
Q1 2017 | $574,000 | +2107.7% | 20,472 | +1446.2% | 0.00% | – |
Q4 2016 | $26,000 | -94.6% | 1,324 | -94.9% | 0.00% | – |
Q1 2016 | $478,000 | +819.2% | 25,759 | +803.5% | 0.00% | – |
Q4 2015 | $52,000 | +477.8% | 2,851 | +449.3% | 0.00% | – |
Q3 2015 | $9,000 | -69.0% | 519 | -68.7% | 0.00% | – |
Q2 2015 | $29,000 | -68.1% | 1,660 | -68.4% | 0.00% | – |
Q1 2015 | $91,000 | – | 5,250 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |